Targeting Interleukin-1 in Heart Disease
Authors:
- 22 October 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 128 (17) , 1910-1923
Abstract
No abstract availableKeywords
This publication has 145 references indexed in Scilit:
- Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]The American Journal of Cardiology, 2013
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouseProceedings of the National Academy of Sciences, 2011
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and ProgressionCancer Cell, 2011
- Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110γMolecular Cell, 2011
- Nlrp3: An immune sensor of cellular stress and infectionThe International Journal of Biochemistry & Cell Biology, 2010
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammationProceedings of the National Academy of Sciences, 2010
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2010
- Inflammasome-Mediated Disease Animal Models Reveal Roles for Innate but Not Adaptive ImmunityImmunity, 2009